Eli Lilly says Indiana’s abortion law will lead the drugmaker to grow in other states

Eli Lilly says Indiana’s abortion law will lead the drugmaker to grow in other states


An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.

Mike Segar | Reuters

Drugmaker Eli Lilly, one of the biggest employers in Indiana, said that the state’s newly passed law restricting abortions will cause the company to grow away from its home turf.

Lilly said in a statement on Saturday that it recognizes abortion as a “divisive and deeply personal issue with no clear consensus among the citizens of Indiana.”

“Despite this lack of agreement, Indiana has opted to quickly adopt one of the most restrictive anti-abortion laws in the United States,” Eli Lilly said. “We are concerned that this law will hinder Lilly’s — and Indiana’s — ability to attract diverse scientific, engineering and business talent from around the world. Given this new law, we will be forced to plan for more employment growth outside our home state.”

Indiana’s Legislature on Friday became the first in the nation to pass new legislation restricting access to abortions since the U.S. Supreme Court overturned Roe v. Wade. The state was among the earliest Republican-run state legislatures to debate tighter abortion laws after the Supreme Court ruling in June that removed constitutional protections for the procedure.

Lilly employs about 10,000 people in Indiana, where it has been headquartered in Indianapolis for more than 145 years.

It joins a growing list of companies, including tech giant Apple and denim retailer Levi Strauss that are offering their employees resources for reproductive care in states where restrictions have been put into place.

Eli Lilly noted Saturday that although the pharmaceutical company has expanded its employee health plan coverage to include travel for reproductive services, “that may not be enough for some current and potential employees.”

Indiana’s abortion ban is expected to go into effect on Sept. 15. It comes with some exceptions, including for cases of rape or incest, and for protecting the mother’s life.

President Joe Biden’s administration has also condemned Indiana’s decision. White House Press Secretary Karine Jean-Pierre called it a “devastating step.”

“And, it’s another radical step by Republican legislators to take away women’s reproductive rights and freedom, and put personal health-care decisions in the hands of politicians rather than women and their doctors,” she said in a statement.



Source

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Health

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]

Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Health

Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]

Read More
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More